专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008016887A2 BUSINESS METHOD TO TREAT AND/OR PREVENT A GASTRIC ACID DISORDER WITH A PROTON PUMP INHIBITOR (PPI) AND A CHOLINERGIC AGONIST TO INDUCE RAPID ONSET OF PPI ACTION WITH OR WITHOUT FOOD 审中-公开
标题翻译：使用原料泵抑制剂（PPI）和胆碱激素治疗和/或预防胃酸疾病的业务方法，以诱导或不用食物的PPI行动的快速上升
公开(公告)号：WO2008016887A2
公开(公告)日：2008-02-07
申请号：PCT/US2007074772
申请日：2007-07-30
申请人： GRACEWAY PHARMACEUTICALS LLC , WOLFE M MICHAEL , BROWN LARRY R , MANSO PETER J
发明人： WOLFE M MICHAEL , BROWN LARRY R , MANSO PETER J
IPC分类号： G06Q10/00
CPC分类号： G06Q10/00 , G06Q50/22
摘要： Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without the need for food effect or to be taken with food. The medications comprise a PPI and a cholinergic agonist for inducing rapid onset of PPI action, for increasing the duration of PPI efficacy and for optimizing clinical PPI effectiveness that may be administered at any time of the day or night without food or on an empty stomach, and possibly on an as-needed or on demand basis, In carrying out the methods, a PPI and cholinergic agonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. Preferably, an oral solid dosage form of the present invention allows for release of a proton pump inhibitor at a pH of about 5 or higher, e.g., pH about 5.5, 6, 6.5 or 7, followed by release of a cholinergic agonist within between about 10 minutes and about 60 minutes, preferably within about 15 minutes and about 30 minutes, after release of the proton pump inhibitor from the dosage form, so that it can be adminisisterd at any time of the day or night independent of food or food effect. It is believed that the methods and compositions of the present invention will increase the duration of PPI efficacy by between at least about 5 fold and about 10 fold or even about 20 fold, as compared to the duration of PPI efficacy derived from current PPI dosage forms adminsitered alone and without food or a food effect. Kits comprising a PPI, a cholinergic agonist and optionally an antacid are disclosed, such as kits containing each drug in conventional and commercially available dry or liquid dosage forms for simultaneous or concomitant administration or in dry dosage forms to provide for the easy preparation of a liquid composition from the dry dosage forms. These new medications and methods will simplify the traditional continous PPI regimen and improve patient compliance.
摘要翻译：公开了药物质子泵抑制剂（PPI）药物和方法，用于预防和/或治疗以白天或夜间的任何时间胃酸分泌异常为特征的胃肠道疾病，而不需要食物作用或与食物一起服用。药物包括PPI和用于诱导PPI作用的快速发作的胆碱能激动剂，用于增加PPI功效的持续时间和优化可在白天或晚上的任何时间没有食物或空腹时施用的临床PPI有效性，并且可能在需要或按需的基础上。在进行该方法时，PPI和胆碱能激动剂可一起施用为液体或固体形式的单次单一剂量，或一起施用，但分别作为液体或固体或其组合。优选地，本发明的口服固体剂型允许质子泵抑制剂在pH约为5或更高，例如pH约5.5,6,6.5或7的情况下释放，随后将胆碱能激动剂释放在约在质子泵抑制剂从剂型中释放出来之后10分钟和约60分钟，优选在约15分钟和约30分钟之内，使得它可以在白天或晚上的任何时间被独立于食物或食物效应管理。据信本发明的方法和组合物将PPI效力的持续时间提高至少约5倍至约10倍或甚至约20倍，与从当前PPI剂型形成的PPI功效的持续时间相比较单独管理，没有食物或食物的影响。公开了包含PPI，胆碱能激动剂和任选的抗酸剂的试剂盒，例如用于同时或伴随给药的常规和市售干燥或液体剂型中的每种药物的试剂盒，或用于干燥剂型，以提供易于制备液体干剂型的组成。这些新的药物和方法将简化传统的连续PPI方案并改善患者的依从性。

2. 发明申请

WO2011008324A1 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS 审中-公开
标题翻译：较低剂量强度液体制剂和短期剂量方案用于治疗一般和周期性的战争
公开(公告)号：WO2011008324A1
公开(公告)日：2011-01-20
申请号：PCT/US2010/033245
申请日：2010-04-30
申请人： GRACEWAY PHARMACEUTICALS, LLC , NORDSIEK, Michael T. , LEVY, Sharon F. , LEE, James H. , KULP, James H. , BALAJI, Kodumudi S. , MENG, Tze-Chiang , WU, Jason J. , BAHM, Valyn S. , BABILON, Robert
发明人： NORDSIEK, Michael T. , LEVY, Sharon F. , LEE, James H. , KULP, James H. , BALAJI, Kodumudi S. , MENG, Tze-Chiang , WU, Jason J. , BAHM, Valyn S. , BABILON, Robert
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06 , A61K31/44 , A61K47/10 , A61K47/12
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1 isobuty 1-1 H-imidazo [4, 5 -c] -quinolin-4-amine or 1 -(2-methylpropyl)- 1 H-imidazo [4,5 -c] quinolin-4-arnme, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara ® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara ® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
摘要翻译：用于局部或透皮递送1种异丁基-1H-咪唑并[4,5-C-] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-d] c]喹啉-4-胺，即咪喹莫特，用于治疗生殖器/肛门周围疣的时间短于目前为商业可用的5％咪喹莫特乳膏所规定的治疗时间，目前由美国食品和药物管理局（FDA）批准 “），被公开和描述。更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣具有可接受的安全性和给药方案，其比目前由美国食品和药物批准的给药方案更短，更方便患者使用还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（“FDA”）。

3. 发明申请

WO2008118765A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118765A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057761
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了当用于治疗受皮肤病症影响的儿童时用于增强咪喹莫特安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。咪喹莫特的局部和/或透皮递送，包括霜剂，软膏，凝胶，洗剂，药膏和压敏粘合剂组合物，用于治疗儿童皮肤病，即传染性软疣，病毒感染如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，并诱导干扰素生物合成。

4. 发明申请

WO2008118762A9 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：使用IMIQUIMOD治疗患有皮肤疾病的儿童治疗儿童时的安全性的方法和包装
公开(公告)号：WO2008118762A9
公开(公告)日：2011-01-06
申请号：PCT/US2008057758
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS LLC , SLADE HERBERT B , LEE JAMES H
发明人： SLADE HERBERT B , LEE JAMES H
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat chiidren affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*109/L or a decrease in median absolute neutrophil count by about 1.42*109/L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatologica! disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了用于增强咪喹莫特用于治疗受皮肤疾病影响的儿童的安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4 * 109 / L或中位绝对嗜中性粒细胞计数降低约1.42 * 109 / L。咪喹莫特的局部和/或透皮给药，包括霜剂，软膏，凝胶，洗剂，药膏和压敏胶粘剂组合物以治疗皮肤病！公开了儿童疾病，即传染性软体动物，病毒感染，例如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

5. 发明申请

WO2010080345A1 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING ACTINIC KERATOSIS 审中-公开
标题翻译：较低剂量强度液体制剂和短期剂量治疗药物治疗方案
公开(公告)号：WO2010080345A1
公开(公告)日：2010-07-15
申请号：PCT/US2009/067759
申请日：2009-12-11
申请人： GRACEWAY PHARMACEUTICALS, LLC , NORDSIEK, Michael, T. , LEVY, Sharon, F. , LEE, James, H. , KULP, James, H. , BALAJI, Kodumudi, S. , MENG, Tze-Chiang , WU, Jason, J. , BAHM, Valyn, S. , BABILON, Robert
发明人： NORDSIEK, Michael, T. , LEVY, Sharon, F. , LEE, James, H. , KULP, James, H. , BALAJI, Kodumudi, S. , MENG, Tze-Chiang , WU, Jason, J. , BAHM, Valyn, S. , BABILON, Robert
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06 , A61K9/7061 , A61K31/437 , A61K31/47 , A61K47/10 , A61K47/12 , A61K47/14
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1 H -imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylρropyl)- 1 H -imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara ® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration ("FDA"), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration ("FDA") for Aldara ® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
摘要翻译：用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基羰基）-1H-咪唑并[4,5 -c]喹啉-4-胺，即咪喹莫特，用于治疗短时间疗法的光化性角化病，比目前为市售的5％咪喹莫特乳膏所规定的，如美国食品和药物管理局（FDA）批准 “），被公开和描述。更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案还公开和描述了用于Aldara 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

6. 发明申请

WO2006099275A3 METHOD OF TREATING ACTINIC KERATOSIS 审中-公开
标题翻译：治疗药物治疗的方法
公开(公告)号：WO2006099275A3
公开(公告)日：2007-10-25
申请号：PCT/US2006008868
申请日：2006-03-14
申请人： 3M INNOVATIVE PROPERTIES CO , GRACEWAY PHARMACEUTICALS LLC , MEDA AB , LEE JAMES H , FOX TERRANCE L
发明人： LEE JAMES H , FOX TERRANCE L
IPC分类号： A61K31/4745
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06
摘要： A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.
摘要翻译：一种治疗光化性角化病的方法，包括每周两次局部应用于光化性角化病病变，持续8周，包含2-甲基-1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1 ，5]萘啶-4-胺。

7. 发明申请

WO2006074046A3 PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE 审中-公开
公开(公告)号：WO2006074046A3
公开(公告)日：2006-07-13
申请号：PCT/US2005/047375
申请日：2005-12-28
申请人： 3M INNOVATIVE PROPERTIES COMPANY , GRACEWAY PHARMACEUTICALS, LLC , MEDA AB , MARTIN, Hugues , ACH, David , TOUSSAINT, Clement , DUBOIS, Fabrice
发明人： MARTIN, Hugues , ACH, David , TOUSSAINT, Clement , DUBOIS, Fabrice
IPC分类号： C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D471/02
摘要： The invention provides various processes for preparing 2-methyl-1-(2-methylpropyl)-1 H -imidazo[4,5-c][1,5]naphthyridin-4-amine.

8. 发明申请

WO2012019158A3 PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM 审中-公开
标题翻译：用于储存和分配多种经过精确测定的IMIQUIMOD CREAM单位剂量的泵系统和方法
公开(公告)号：WO2012019158A3
公开(公告)日：2012-05-10
申请号：PCT/US2011046847
申请日：2011-08-05
申请人： GRACEWAY PHARMACEUTICALS LLC , NORDSIEK MICHAEL T , BALAJI KODUMUDI S
发明人： NORDSIEK MICHAEL T , BALAJI KODUMUDI S
IPC分类号： A61K31/4745 , B67B5/00
CPC分类号： A61M35/003 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/06 , A61K31/4745 , A61K47/10 , B05B11/0024 , B05B11/0037 , B05B11/0048 , B05B11/3001 , B05B11/3042 , B05B11/3047
摘要： The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation ("pump systems") and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosalassociated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).
摘要翻译：本发明涉及无空气存储和分配系统，其包括预先填充有局部半固体咪喹莫特药物制剂（“泵系统”）的泵或分配包装，以及用于从泵系统存储和分配多个精确的测量并且均匀单位剂量的局部用咪喹莫特药物制剂，更具体地涉及用局部用咪喹莫特药物乳膏预填充的泵系统和用于递送多个精确测量的单位剂量局部用咪喹莫特药用乳膏的方法，以及用于使用受控输送泵系统来储存和分配局部治疗真皮和粘膜相关病症（例如外生殖器疣和/或肛周疣（EGW））的局部用咪喹莫特药物乳膏的多个一致且精确测量的单位剂量，，光化性角化病或光化性角化病（AK或AK）和浅表基底细胞癌（SBCC）。

9. 发明申请

WO2012019158A2 PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM 审中-公开
标题翻译：用于储存和分配多种精确测量的IMIQUIMOD CREAM单位的泵系统和方法
公开(公告)号：WO2012019158A2
公开(公告)日：2012-02-09
申请号：PCT/US2011/046847
申请日：2011-08-05
申请人： GRACEWAY PHARMACEUTICALS, LLC , NORDSIEK, Michael, T. , BALAJI, Kodumudi, S.
发明人： NORDSIEK, Michael, T. , BALAJI, Kodumudi, S.
IPC分类号： A61M35/00
CPC分类号： A61M35/003 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/06 , A61K31/4745 , A61K47/10 , B05B11/0024 , B05B11/0037 , B05B11/0048 , B05B11/3001 , B05B11/3042 , B05B11/3047
摘要： The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation ("pump systems") and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosalassociated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).
摘要翻译：本发明涉及无空气储存和分配系统，其包括预先填充有局部半固体咪喹莫特药物制剂（“泵系统”）的泵或分配包装以及用于从泵系统存储和分配多个精确的测量和均匀单位剂量的局部半固体咪喹莫特药物制剂，更具体地涉及预先填充有局部咪喹莫特药物霜剂的泵系统和用于递送多个精确测量的单位剂量的局部咪喹莫特药物霜剂的方法，以及用于使用受控递送泵系统来存储和分配多个一致且精确测量的单位剂量的局部咪喹莫特药物霜，用于局部治疗皮肤和粘膜相关病症，例如外部生殖器疣和/或肛门周围疣（EGW），光化性角化病或光化性角化病（AK或AK）和浅表性基底细胞癌（SBCC）。

10. 发明申请

WO2008118762A1 METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS 审中-公开
标题翻译：当使用IMIQUIMOD治疗患有皮肤病的儿童时，加强安全的方法和包装
公开(公告)号：WO2008118762A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/057758
申请日：2008-03-20
申请人： GRACEWAY PHARMACEUTICALS, LLC , SLADE, Herbert, B. , LEE, James, H.
发明人： SLADE, Herbert, B. , LEE, James, H.
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/44
摘要： Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat chiidren affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10 9 /L or a decrease in median absolute neutrophil count by about 1.42*10 9 /L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure- sensitive adhesive compositions to treat dermatologica! disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type Il Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
摘要翻译：公开了用于增强咪喹莫特用于治疗受皮肤疾病影响的儿童的安全性的药物包装和方法。更特别地，通过向儿童，儿童的监护人，包括父母和保健专业人员提供信息来增强咪喹莫特使用的安全性，当咪喹莫特治疗用于治疗儿童时，可观察到咪喹莫特的全身吸收和其他作用约2至约12岁。全身吸收的实例包括小于约2ng / mL的血清咪喹莫特浓度，白细胞计数中位数降低约1.4×10 9 / L或中位绝对嗜中性粒细胞计数降低约1.42×10 9 / L。局部和/或透皮给药咪喹莫特，包括霜剂，软膏，凝胶，洗剂，药膏和压敏胶粘剂组合物以治疗皮肤病！公开了儿童疾病，即传染性软体动物，病毒感染，例如I型或II型单纯疱疹感染和尖锐湿疣，生殖器疣和肛周疣，光化性角化病和浅表性基底细胞癌，以及诱导干扰素生物合成。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式